000			01996 a2200589 4500
005			20250517160945.0
264		0	_c20171016
008			201710s 0 0 eng d
022			_a1349-7006
024	7		_a10.1111/cas.13301 _2doi
040			_aNLM _beng _cNLM
100	1		_aYutani, Shigeru
245	0	0	_aFeasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies. _h[electronic resource]
260			_bCancer science _cSep 2017
300			_a1732-1738 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aCancer Vaccines _xadministration & dosage
650	0	4	_aCarcinoma, Hepatocellular _xmortality
650	0	4	_aChemoembolization, Therapeutic
650	0	4	_aCombined Modality Therapy
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aFeasibility Studies
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aKaplan-Meier Estimate
650	0	4	_aLiver Neoplasms _xmortality
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNiacinamide _xadministration & dosage
650	0	4	_aPhenylurea Compounds _xadministration & dosage
650	0	4	_aPrecision Medicine
650	0	4	_aSorafenib
650	0	4	_aT-Lymphocytes, Cytotoxic _xphysiology
650	0	4	_aTreatment Outcome
650	0	4	_aVaccination
650	0	4	_aVaccines, Subunit _xadministration & dosage
700	1		_aShirahama, Takahisa
700	1		_aMuroya, Daisuke
700	1		_aMatsueda, Satoko
700	1		_aYamaguchi, Rin
700	1		_aMorita, Michi
700	1		_aShichijo, Shigeki
700	1		_aYamada, Akira
700	1		_aSasada, Tetsuro
700	1		_aItoh, Kyogo
773	0		_tCancer science _gvol. 108 _gno. 9 _gp. 1732-1738
856	4	0	_uhttps://doi.org/10.1111/cas.13301 _zAvailable from publisher's website
999			_c27285060 _d27285060